Brello Health review
The card advertises a monthly figure. Renewals bill every eleven weeks, not every three months.
The verdict
Brello Health advertises semaglutide at $133 a month on a three-month minimum. Renewals bill $399 every eleven weeks. Eleven weeks is 2.53 calendar months, not three.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- States
- 35
- From
- From $133/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- 35 states
Brello Health sells both molecules by injection across 35 states. Two lines carry figures. There is no one-month option. A three-month prepay is mandatory.
Who writes the prescription, and what do they see?
A prescription precedes shipping. The pages describe plans rather than clinicians. The intake is not documented. What is documented is the billing cycle, in the checkout rather than on the card.
Two terms sit behind the advertised figure. Renewals run every eleven weeks, not every calendar quarter. And the prepay is mandatory, so nobody buys a single month. Both sit in a footnote under the headline figure.
What happens when the dose goes up?
Nothing is published about what the figure does at a higher dose. On an eleven-week cycle that gap is wider than usual. A buyer commits most of a titration window at a price whose behavior is unstated.
What the price includes
The advertised $133 is $399 divided by three months. Renewals then bill $399 every eleven weeks, which is 2.53 calendar months. A year of renewals bills more often than a quarterly reading suggests. Tirzepatide follows the same pattern: $166 advertised, $499 every eleven weeks. The $599 and $749 strikethroughs are anchors and are never charged.
What it claims, and what it cites
Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: The billing cycle appears at checkout
- Strength: Coverage stated across 35 states
- Strength: Both molecules carry a figure
- Limitation: Renewals bill every eleven weeks
- Limitation: The headline divides by three, not 2.53
- Limitation: A three-month prepay is mandatory
- Limitation: Anchor prices are never charged
What the evidence says about this kind of treatment
The assessment above is about Brello Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who reads the checkout before the card and can prepay a quarter.
- Wrong for
- A reader taking the advertised monthly figure at face value.
The evidence behind what Brello Health prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Brello Health compares
| Seller | Who it suits | Go |
|---|---|---|
 Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | See Enhance MD → |
 Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | See Pallas Health → |
 Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | See Harper Meds → |
More GLP-1 telehealth sellers reviews: TeleHealth MedTeleHealth Weight SolutionsTelePeptideTeleSlim ClinicTeleZen MDTell Her Doc
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Is the advertised figure a monthly price?
- Not quite. The first $399 covers the three-month minimum. Renewals then bill every eleven weeks, which is 2.53 calendar months rather than three.
- Can I buy one month?
- No. There is no one-month option and the three-month prepay is mandatory.
- Are the strikethrough prices real?
- No. $599 and $749 are anchors. Nothing on the pages indicates either is charged.
- Is Brello Health legit?
- Brello Health is a GLP-1 telehealth sellers service. Its stated availability: 35 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is Brello Health expensive compared with other GLP-1 telehealth sellers?
- Brello Health publishes a starting figure of $133/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Brello Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.